CN Patent

CN114591433A — 抗pd-1抗体、可活化抗pd-1抗体及其使用方法

Assigned to Cytomx Therapeutics Inc · Expires 2022-06-07 · 4y expired

What this patent protects

本发明涉及抗PD‑1抗体、可活化抗PD‑1抗体及其使用方法。本发明一般涉及特异性结合程序性细胞死亡蛋白1（PD‑1）的抗体、特异性结合PD‑1的可活化抗体以及制备这些抗PD‑1抗体和抗PD‑1可活化抗体和在多种治疗、诊断和预防适应症中使用它们的方法。

USPTO Abstract

本发明涉及抗PD‑1抗体、可活化抗PD‑1抗体及其使用方法。本发明一般涉及特异性结合程序性细胞死亡蛋白1（PD‑1）的抗体、特异性结合PD‑1的可活化抗体以及制备这些抗PD‑1抗体和抗PD‑1可活化抗体和在多种治疗、诊断和预防适应症中使用它们的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114591433A
Jurisdiction
CN
Classification
—
Expires
2022-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Cytomx Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.